<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00004072</url>
  </required_header>
  <id_info>
    <org_study_id>CWRU1A96</org_study_id>
    <secondary_id>U01CA062502</secondary_id>
    <secondary_id>P30CA043703</secondary_id>
    <secondary_id>CWRU-1A96</secondary_id>
    <secondary_id>NCI-T97-0021</secondary_id>
    <nct_id>NCT00004072</nct_id>
  </id_info>
  <brief_title>O6-benzylguanine And Carmustine in Treating Patients With Multiple Myeloma</brief_title>
  <official_title>Phase II Trial of O6-Benzylguanine (NSC 637037) and BCNU in Patients With Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Case Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Case Comprehensive Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die. Combining more than one drug may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of combining O6-benzylguanine with&#xD;
      carmustine in treating patients who have previously untreated, refractory, or relapsing&#xD;
      multiple myeloma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Evaluate the efficacy of O6-benzylguanine combined with carmustine in patients with&#xD;
           previously untreated or refractory multiple myeloma.&#xD;
&#xD;
        -  Assess the effects of O6-benzylguanine on bone marrow myeloma cells in this patient&#xD;
           population.&#xD;
&#xD;
      OUTLINE: Patients receive O6-benzylguanine IV over 60 minutes followed 1 hour later by&#xD;
      carmustine IV over 60 minutes. Courses repeat every 6 weeks in the absence of disease&#xD;
      progression or unacceptable toxicity. Patients receive 2 additional courses beyond attainment&#xD;
      of best response (partial or complete response or stable or plateau disease).&#xD;
&#xD;
      Patients are followed every 2 months.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 30 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 1999</start_date>
  <completion_date type="Actual">September 2004</completion_date>
  <primary_completion_date type="Actual">August 2004</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate the efficacy of O6-benzylguanine combined with carmustine in patients with previously untreated or refractory multiple myeloma.</measure>
    <time_frame>Every 6 weeks in the absence of disease progression or unacceptable toxicity. Patients receive 2 additional courses beyond attainment of best response. Patients are followed every 2 months.</time_frame>
  </primary_outcome>
  <enrollment type="Actual">17</enrollment>
  <condition>Multiple Myeloma and Plasma Cell Neoplasm</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>O6-benzylguanine</intervention_name>
    <description>Patients receive O6-benzylguanine IV over 60 minutes. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity. Patients receive 2 additional courses beyond attainment of best response.</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carmustine</intervention_name>
    <description>Followed 1 hour later by carmustine IV over 60 minutes. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity. Patients receive 2 additional courses beyond attainment of best response.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed progressive multiple myeloma, meeting 1 of the following&#xD;
             criteria:&#xD;
&#xD;
               -  Previously untreated&#xD;
&#xD;
               -  Primary refractory&#xD;
&#xD;
               -  Relapsing disease&#xD;
&#xD;
          -  Major criteria:&#xD;
&#xD;
               -  Plasmacytomas on tissue biopsy&#xD;
&#xD;
               -  Bone marrow plasmacytosis with greater than 30% plasma cells&#xD;
&#xD;
               -  Monoclonal globulin spike on serum electrophoresis&#xD;
&#xD;
                    -  Greater than 3.5 g/dL for G peaks or greater than 2.0 g for A peaks&#xD;
&#xD;
                    -  Greater than 1.0 g/24 hours of kappa or lambda light chain excretion on&#xD;
                       urine electrophoresis in the absence of amyloidosis&#xD;
&#xD;
          -  Minor criteria:&#xD;
&#xD;
               -  10%-30% bone marrow plasmacytosis (criterion A)&#xD;
&#xD;
               -  Presence of monoclonal globulin spike but less than the levels under major&#xD;
                  criteria (criterion B)&#xD;
&#xD;
               -  Lytic bone lesions (criterion C)&#xD;
&#xD;
               -  IgM less than 50 mg/dL, IgA less than 100 mg/dL, or IgG less than 600 mg/dL&#xD;
                  (criterion D)&#xD;
&#xD;
          -  Must meet one of the following:&#xD;
&#xD;
               -  A minimum of 1 major criterion and 1 minor criterion&#xD;
&#xD;
               -  3 minor criteria, including criteria A and B&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  At least 12 weeks&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  WBC greater than 3,000/mm^3&#xD;
&#xD;
          -  Platelet count greater than 100,000/mm^3&#xD;
&#xD;
          -  Absolute neutrophil count greater than 1,500/mm^3&#xD;
&#xD;
          -  Hemoglobin greater than 9 g/dL (transfusions allowed)&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin less than 1.5 mg/dL&#xD;
&#xD;
          -  AST/ALT less than 2 times normal&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine no greater than 2.0 mg/dL OR&#xD;
&#xD;
          -  Creatinine clearance greater than 60 mL/min&#xD;
&#xD;
          -  Calcium less than 14 mg/dL&#xD;
&#xD;
        Pulmonary:&#xD;
&#xD;
          -  No prior or concurrent active, symptomatic respiratory disease&#xD;
&#xD;
          -  Corrected DLCO at least 60% predicted&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Controlled diabetes mellitus allowed&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for 2 months after study&#xD;
             participation&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  No more than 1 prior chemotherapy regimen containing an alkylating agent for multiple&#xD;
             myeloma&#xD;
&#xD;
          -  At least 4 weeks since prior chemotherapy&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Prior corticosteroids for multiple myeloma allowed&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  No prior pelvic radiotherapy or radiotherapy to more than 25% of bone marrow&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  Not specified&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stanton L. Gerson, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Chicago Cancer Research Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637-1470</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106-5065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MetroHealth Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2010</verification_date>
  <study_first_submitted>December 10, 1999</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>June 9, 2010</last_update_submitted>
  <last_update_submitted_qc>June 9, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 11, 2010</last_update_posted>
  <responsible_party>
    <name_title>Stanton L. Gerson, MD</name_title>
    <organization>Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center</organization>
  </responsible_party>
  <keyword>refractory multiple myeloma</keyword>
  <keyword>stage I multiple myeloma</keyword>
  <keyword>stage II multiple myeloma</keyword>
  <keyword>stage III multiple myeloma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Plasmacytoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carmustine</mesh_term>
    <mesh_term>O(6)-benzylguanine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

